Given that VPA can cross the blood-brain barrier, we investigated the effect of VPA on the expression of surface NKG2D ligands in glioma cell lines and attempted to combine VPA and NKG2D CAR-T to treat glioblastoma in this study. The gene discussed is KLRK1; the disease is central nervous system cancer.